Clinical Trials for Mesothelioma Patients—Vaccine Therapy and GM-CSF: Patient Characteristics Criteria

Read about the concurrent therapy for a current clinical trial to test vaccine therapy GM-CSF on mesothelioma patients. . Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Patient Characteristics:

• Karnofsky performance status 70-100%
• Absolute neutrophil count = 1,000/mm³
• Platelet count > 50,000/mm³ (except for myelodysplastic syndromes where parameter is > 20,000/mm³ and not transfusion dependent)
• Bilirubin = 2.0 mg/dL
• AST and ALT = 2.5 times upper limit of normal
• Creatinine = 2.0 mg/dL
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active infection requiring systemic antibiotics, antiviral, or antifungal treatments
• No serious unstable medical illness

Prior Concurrent Therapy:

• See Disease Characteristics
• At least 4 weeks since prior chemotherapy or radiotherapy
• No concurrent systemic corticosteroids

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.